Ken Mulvany is a serial entrepreneur and investor with more than 20 years of business leadership experience. Ken is the Founder of BenevolentAI, where he now serves on its Board of Directors. He was previously Founder and CEO of Proximagen, a biotech company developing medicines for central nervous system disorders, which he sold in 2012.
Ken is a passionate environmentalist and philanthropist. He was the Chairman of the Trustees of the Cure Parkinson’s Trust, and he now sits on several advisory boards including the Advisory Board for Oxford Sciences Innovations.